Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...56789101112131415...401402»
  • ||||||||||  Review, Journal:  Effects and mechanisms of APP and its cleavage product A? in the comorbidity of sarcopenia and Alzheimer's disease. (Pubmed Central) -  Dec 10, 2024   
    Recent studies have shown that excessive accumulation and aberrant expression of APP in muscle lead to pathological muscle lesions, but the pathogenic mechanism by which APP and its proteolytic cleavage products act in skeletal muscle is less well understood. By summarizing and analyzing the literature concerning the role, pathogenicity and pathological mechanisms of APP and its cleavage products in the nervous system and muscles, we aimed to explore the intrinsic pathological mechanisms of myocerebral comorbidities and to provide new perspectives and theoretical foundations for the prevention and treatment of AD and sarcopenia comorbidities.
  • ||||||||||  cisplatin / Generic mfg.
    Journal:  Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function. (Pubmed Central) -  Dec 10, 2024   
    By summarizing and analyzing the literature concerning the role, pathogenicity and pathological mechanisms of APP and its cleavage products in the nervous system and muscles, we aimed to explore the intrinsic pathological mechanisms of myocerebral comorbidities and to provide new perspectives and theoretical foundations for the prevention and treatment of AD and sarcopenia comorbidities. Among MIBC patients who received NAC, sarcopenia was associated with higher odds of NAC-associated renal toxicity and may increase risk of renal toxicity among patients with borderline renal function.
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE) (clinicaltrials.gov) -  Dec 10, 2024   
    P=N/A,  N=60, Recruiting, 
    Sarcopenia may play a significant role in predicting the prognosis of acute pancreatitis. Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Sep 2027 | Trial primary completion date: May 2026 --> Aug 2026
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  COOLEY- Study: ACute on ChrOnic Liver FailurE Using the CYtosorb Device (clinicaltrials.gov) -  Dec 10, 2024   
    P=N/A,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Sep 2027 | Trial primary completion date: May 2026 --> Aug 2026 Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Sep 2027 | Trial primary completion date: Jun 2026 --> Sep 2026
  • ||||||||||  Review, Journal:  Stroke-Related Sarcopenia: Pathophysiology and Diagnostic Tools. (Pubmed Central) -  Dec 9, 2024   
    Various evaluation tools are available to diagnose this condition, assessing skeletal muscle mass, muscle strength, and physical function. However, due to the limitations of traditional sarcopenia diagnostic criteria in the context of stroke, there is pressing need to establish diagnostic standards that accurately reflect the disabilities experienced by patients with stroke.
  • ||||||||||  Journal:  Are Hyperlipidaemia and Insulin Resistance Risks For Sarcopenia? (Pubmed Central) -  Dec 9, 2024   
    This study suggests that high triglyceride levels may represent a risk factor associated with sarcopenia and that sarcopenia may be associated with conditions such as high BMI, insulin resistance, and dyslipidaemia. Controlling lipid levels could be beneficial in reducing the risk of sarcopenia.
  • ||||||||||  Journal:  Mitochondrial pathways and sarcopenia in the geroscience era. (Pubmed Central) -  Dec 8, 2024   
    Several biomarkers spanning MQC, inflammation, metabolism, intercellular communication, and gut microbiota have been linked to sarcopenia. Findings from these initial studies hold promise to inform geroscience-based research in the field of sarcopenia by offering a plausible biological framework for developing gerotherapeutics and monitoring their effects.
  • ||||||||||  Observational data, Journal:  Limited predictive value of bioelectrical phase angle for the development of sarcopenia in older Europeans. (Pubmed Central) -  Dec 8, 2024   
    Findings from these initial studies hold promise to inform geroscience-based research in the field of sarcopenia by offering a plausible biological framework for developing gerotherapeutics and monitoring their effects. As an indicator of cells function, PhA could be a potential useful early marker in identifying older people at risk of developing sarcopenia but its practical applicability remains uncertain with the present data.
  • ||||||||||  Review, Journal:  GDF15/MIC-1: a stress-induced immunosuppressive factor which promotes the aging process. (Pubmed Central) -  Dec 7, 2024   
    Immunosuppressive responses not only suppress chronic inflammatory processes but they evoke many detrimental effects in aged tissues, such as cellular senescence, fibrosis, and tissue atrophy/sarcopenia. It seems that the survival functions of GDF15 go awry in persistent inflammation thus promoting the aging process and age-related diseases.
  • ||||||||||  Review, Journal:  Gut microbiome and bone health: update on mechanisms, clinical correlations, and possible treatment strategies. (Pubmed Central) -  Dec 7, 2024   
    In this systematic review, we provide an overview of the mechanisms involved in the gut-bone axis, with a particular focus on microbiome function and microbiome-derived mediators including short-chain fatty acids. We also review the current evidence linking gut microbiota dysbiosis with osteopenia and osteoporosis, and the results of the intervention studies on pre-, pro-, or post-biotics targeting bone mineral density loss in both animal models and human beings, indicating knowledge gaps and highlighting possible avenues for future research.
  • ||||||||||  Journal:  Addressing frailty in older adults: an integrated challenge for health, science, and society. (Pubmed Central) -  Dec 7, 2024   
    Tackling frailty is not only a health imperative but also a social and ethical responsibility. By addressing the intertwined health, scientific, and social challenges of frailty, we can ensure healthy and equitable aging for all, reflecting our commitment to improving the quality of life for older adults.
  • ||||||||||  Review, Journal:  Diet and exercise in frailty and sarcopenia. Molecular aspects. (Pubmed Central) -  Dec 7, 2024   
    We aim to highlight the molecular pathways that are involved in frailty and sarcopenia. The possibility to effectively target these signaling pathways in clinical practice to delay muscle aging is also discussed.
  • ||||||||||  Review, Journal:  Muscle aging and sarcopenia: The pathology, etiology, and most promising therapeutic targets. (Pubmed Central) -  Dec 7, 2024   
    This review will discuss age-related changes in healthy muscle and our current understanding of how this can deteriorate into sarcopenia. As our elderly population continues to grow, we must understand sarcopenia and find treatments that allow individuals to maintain independence and dignity throughout an extended lifespan.
  • ||||||||||  Review, Journal, Immunomodulating:  Immunomodulation: A new approach to cancer cachexia, potentially suitable for aging. (Pubmed Central) -  Dec 7, 2024   
    Along this line, cancer- and aging-associated muscle wasting likely coexist in the same patients. Since both conditions share some of the underlying mechanisms, the potential effectiveness of immunomodulation on sarcopenia of aging is discussed.
  • ||||||||||  Effect of Sarcopenia and Nutritional Risk Factors in Patients with Multiple Myeloma () -  Dec 7, 2024 - Abstract #ASH2024ASH_8940;    
    Multivariate analysis indicated that sarcopenia emerged as a significant and independent predictor of inferior OS (HR=1.820, P=0.048) in NDMM patients.Conclusion : In conclusion, sarcopenia served as an autonomous prognostic indicator OS in individuals with NDMM. The integration of PNI and CONUT with sarcopenia was effective in predicting prognosis in MM patients.
  • ||||||||||  Review, Journal:  Research progress on the correlation between estrogen and estrogen receptor on postmenopausal sarcopenia. (Pubmed Central) -  Dec 6, 2024   
    This paper reviews the literature on the impact of estrogen on postmenopausal skeletal muscle diseases and the underlying molecular mechanisms, especially in terms of mitochondrial metabolism. In summary, estrogen plays an important role in the health of skeletal muscle in postmenopausal women, and its impact on mitochondrial function and homeostasis offers potential targets for the development of new strategies to treat sarcopenia.
  • ||||||||||  Observational data, Retrospective data, Journal:  Evaluation of Sarcopenia screening indices as predictors of mortality in older patients with Alzheimer's disease. (Pubmed Central) -  Dec 5, 2024   
    Given the limitations of the NHANES study, further researches are required to clarify the existence of these relationships. This study showed that only Cr/CysC*100 was effective in the prediction of mortality in older individuals with AD and sarcopenia and that neutrophils/lymphocytes, platelets/lymphocytes, and AST/ALT were not effective as predictors.
  • ||||||||||  Journal:  The finger-ring test as an indicator of muscle mass estimated by dual-energy X-ray absorptiometry in an adult community-dwelling population. (Pubmed Central) -  Dec 5, 2024   
    This study showed that only Cr/CysC*100 was effective in the prediction of mortality in older individuals with AD and sarcopenia and that neutrophils/lymphocytes, platelets/lymphocytes, and AST/ALT were not effective as predictors. By demonstrating an association between the appendicular lean soft tissue mass estimated by DXA and the FRT, these results strengthen the utility of this simple self-test as an indicator of muscle mass, which can be used in the primary prevention of muscle mass decline and its recovery.
  • ||||||||||  Review, Journal:  Sarcopenia in interstitial lung disease. (Pubmed Central) -  Dec 5, 2024   
    Accordingly, if identified, targeted interventions should be considered. Validated diagnostic criteria exist, but the optimal use of medical imaging techniques in this patient cohort remains an area of uncertainty.
  • ||||||||||  Retrospective data, Review, Journal:  Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis. (Pubmed Central) -  Dec 5, 2024   
    Compared with the controls, GLP-1 receptor-based agonist users experienced greater reductions in fat body mass, with body shaping effects in terms of both subcutaneous fat mass and visceral fat mass. Although greater reductions in lean body mass were also observed in GLP-1 receptor-based agonist users, the changes in lean mass percentage were comparable between the users and non-users.